Skip to main content
Top
Published in: European Journal of Nuclear Medicine and Molecular Imaging 2/2016

Open Access 01-02-2016 | Original Article

The impact of acquisition time of planar cardiac 123I-MIBG imaging on the late heart to mediastinum ratio

Authors: Aukelien C. Dimitriu-Leen, Alessia Gimelli, Imad al Younis, Caroline E. Veltman, Hein J. Verberne, Ron Wolterbeek, Silvia Zandbergen-Harlaar, Jeroen J. Bax, Arthur J. H. A. Scholte

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 2/2016

Login to get access

Abstract

Purpose

The aim of this study was to investigate whether performing the late cardiac 123I-metaiodobenzylguanidine (MIBG) scan earlier than 4 h post-injection (p.i.) has relevant impact on the late heart to mediastinum ratio (H/M ratio) in patients with heart failure (HF).

Methods

Forty-nine patients with HF (median left ventricular ejection fraction of 31 %, 51 % ischaemic HF) referred for cardiac 123I-MIBG scintigraphy were scanned at 15 min (early) p.i. and at 1, 2, 3 and 4 h (late) p.i. of 123I-MIBG. Late H/M ratios were calculated and evaluated using a linear mixed model with the mean late H/M ratio at 4 h p.i. as a reference. A difference in late H/M ratios of more than 0.10 between the different acquisition times in comparison with the late H/M ratio at 4 h p.i. was considered as clinically relevant.

Results

Statistically significant mean differences were observed between the late H/M ratios at 1, 2 and 3 h p.i. compared with the late H/M ratio at 4 h p.i. (0.09, 0.05 and 0.02, respectively). However, the mean differences did not exceed the cut-off value of 0.10. On an individual patient level, compared to the late H/M ratio at 4 h p.i., the late H/M ratios at 1, 2 and 3 h p.i. differed more than 0.10 in 24 (50 %), 9 (19 %) and 2 (4 %) patients, respectively.

Conclusion

Variation in acquisition time of 123I-MIBG between 2 and 4 h p.i. does not lead to a clinically significant change in the late H/M ratio. An earlier acquisition time seems to be justified and may warrant a more time-efficient cardiac 123I-MIBG imaging protocol.
Literature
1.
go back to reference Cowie MR, Mosterd A, Wood DA, Deckers JW, Poole-Wilson PA, Sutton GC, et al. The epidemiology of heart failure. Eur Heart J 1997;18(2):208–25.PubMedCrossRef Cowie MR, Mosterd A, Wood DA, Deckers JW, Poole-Wilson PA, Sutton GC, et al. The epidemiology of heart failure. Eur Heart J 1997;18(2):208–25.PubMedCrossRef
2.
go back to reference Meredith IT, Eisenhofer G, Lambert GW, Dewar EM, Jennings GL, Esler MD. Cardiac sympathetic nervous activity in congestive heart failure. Evidence for increased neuronal norepinephrine release and preserved neuronal uptake. Circulation 1993;88(1):136–45.PubMedCrossRef Meredith IT, Eisenhofer G, Lambert GW, Dewar EM, Jennings GL, Esler MD. Cardiac sympathetic nervous activity in congestive heart failure. Evidence for increased neuronal norepinephrine release and preserved neuronal uptake. Circulation 1993;88(1):136–45.PubMedCrossRef
3.
go back to reference Kline RC, Swanson DP, Wieland DM, Thrall JH, Gross MD, Pitt B, et al. Myocardial imaging in man with I-123 meta-iodobenzylguanidine. J Nucl Med 1981;22(2):129–32.PubMed Kline RC, Swanson DP, Wieland DM, Thrall JH, Gross MD, Pitt B, et al. Myocardial imaging in man with I-123 meta-iodobenzylguanidine. J Nucl Med 1981;22(2):129–32.PubMed
4.
go back to reference Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol 2010;55(20):2212–21. doi:10.1016/j.jacc.2010.01.014.PubMedCrossRef Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol 2010;55(20):2212–21. doi:10.​1016/​j.​jacc.​2010.​01.​014.PubMedCrossRef
5.
go back to reference Arora R, Ferrick KJ, Nakata T, Kaplan RC, Rozengarten M, Latif F, et al. I-123 MIBG imaging and heart rate variability analysis to predict the need for an implantable cardioverter defibrillator. J Nucl Cardiol 2003;10(2):121–31. doi:10.1067/mnc.2003.2.PubMedCrossRef Arora R, Ferrick KJ, Nakata T, Kaplan RC, Rozengarten M, Latif F, et al. I-123 MIBG imaging and heart rate variability analysis to predict the need for an implantable cardioverter defibrillator. J Nucl Cardiol 2003;10(2):121–31. doi:10.​1067/​mnc.​2003.​2.PubMedCrossRef
6.
go back to reference Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure. J Nucl Med 2002;43(10):1279–85.PubMed Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure. J Nucl Med 2002;43(10):1279–85.PubMed
7.
go back to reference Boogers MJ, Borleffs CJ, Henneman MM, van Bommel RJ, van Ramshorst J, Boersma E, et al. Cardiac sympathetic denervation assessed with 123-iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patients. J Am Coll Cardiol 2010;55(24):2769–77. doi:10.1016/j.jacc.2009.12.066.PubMedCrossRef Boogers MJ, Borleffs CJ, Henneman MM, van Bommel RJ, van Ramshorst J, Boersma E, et al. Cardiac sympathetic denervation assessed with 123-iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patients. J Am Coll Cardiol 2010;55(24):2769–77. doi:10.​1016/​j.​jacc.​2009.​12.​066.PubMedCrossRef
8.
go back to reference Flotats A, Carrió I, Agostini D, Le Guludec D, Marcassa C, Schäfers M, et al. Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nucl Med Mol Imaging 2010;37(9):1802–12. doi:10.1007/s00259-010-1491-4.PubMedCrossRef Flotats A, Carrió I, Agostini D, Le Guludec D, Marcassa C, Schäfers M, et al. Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nucl Med Mol Imaging 2010;37(9):1802–12. doi:10.​1007/​s00259-010-1491-4.PubMedCrossRef
9.
go back to reference Okuda K, Nakajima K, Sugino S, Kirihara Y, Matsuo S, Taki J, et al. Development and validation of a direct-comparison method for cardiac 123I-metaiodobenzylguanidine washout rates derived from late 3-hour and 4-hour imaging. Eur J Nucl Med Mol Imaging. 2015. doi:10.1007/s00259-015-3173-8. Okuda K, Nakajima K, Sugino S, Kirihara Y, Matsuo S, Taki J, et al. Development and validation of a direct-comparison method for cardiac 123I-metaiodobenzylguanidine washout rates derived from late 3-hour and 4-hour imaging. Eur J Nucl Med Mol Imaging. 2015. doi:10.​1007/​s00259-015-3173-8.
10.
go back to reference Giorgetti A, Burchielli S, Positano V, Kovalski G, Quaranta A, Genovesi D, et al. Dynamic 3D analysis of myocardial sympathetic innervation: an experimental study using 123I-MIBG and a CZT camera. J Nucl Med 2015;56(3):464–9. doi:10.2967/jnumed.114.143669.PubMedCrossRef Giorgetti A, Burchielli S, Positano V, Kovalski G, Quaranta A, Genovesi D, et al. Dynamic 3D analysis of myocardial sympathetic innervation: an experimental study using 123I-MIBG and a CZT camera. J Nucl Med 2015;56(3):464–9. doi:10.​2967/​jnumed.​114.​143669.PubMedCrossRef
11.
go back to reference McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33(14):1787–847. doi:10.1093/eurheartj/ehs104.PubMedCrossRef McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33(14):1787–847. doi:10.​1093/​eurheartj/​ehs104.PubMedCrossRef
12.
go back to reference Verberne HJ, Brewster LM, Somsen GA, van Eck-Smit BL. Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur Heart J 2008;29(9):1147–59. doi:10.1093/eurheartj/ehn113.PubMedCrossRef Verberne HJ, Brewster LM, Somsen GA, van Eck-Smit BL. Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur Heart J 2008;29(9):1147–59. doi:10.​1093/​eurheartj/​ehn113.PubMedCrossRef
13.
go back to reference Nakajo M, Shimabukuro K, Miyaji N, Shimada J, Shirono K, Sakata H, et al. Rapid clearance of iodine-131 MIBG from the heart and liver of patients with adrenergic dysfunction and pheochromocytoma. J Nucl Med 1985;26(4):357–65.PubMed Nakajo M, Shimabukuro K, Miyaji N, Shimada J, Shirono K, Sakata H, et al. Rapid clearance of iodine-131 MIBG from the heart and liver of patients with adrenergic dysfunction and pheochromocytoma. J Nucl Med 1985;26(4):357–65.PubMed
14.
go back to reference Nakajo M, Shimabukuro K, Yoshimura H, Yonekura R, Nakabeppu Y, Tanoue P, et al. Iodine-131 metaiodobenzylguanidine intra- and extravesicular accumulation in the rat heart. J Nucl Med 1986;27(1):84–9.PubMed Nakajo M, Shimabukuro K, Yoshimura H, Yonekura R, Nakabeppu Y, Tanoue P, et al. Iodine-131 metaiodobenzylguanidine intra- and extravesicular accumulation in the rat heart. J Nucl Med 1986;27(1):84–9.PubMed
15.
go back to reference DeGrado TR, Zalutsky MR, Vaidyanathan G. Uptake mechanisms of meta-[123I]iodobenzylguanidine in isolated rat heart. Nucl Med Biol 1995;22(1):1–12.PubMedCrossRef DeGrado TR, Zalutsky MR, Vaidyanathan G. Uptake mechanisms of meta-[123I]iodobenzylguanidine in isolated rat heart. Nucl Med Biol 1995;22(1):1–12.PubMedCrossRef
16.
go back to reference Sisson JC, Shapiro B, Meyers L, Mallette S, Mangner TJ, Wieland DM, et al. Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J Nucl Med 1987;28(10):1625–36.PubMed Sisson JC, Shapiro B, Meyers L, Mallette S, Mangner TJ, Wieland DM, et al. Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J Nucl Med 1987;28(10):1625–36.PubMed
17.
go back to reference Dae MW, De Marco T, Botvinick EH, O’Connell JW, Hattner RS, Huberty JP, et al. Scintigraphic assessment of MIBG uptake in globally denervated human and canine hearts--implications for clinical studies. J Nucl Med 1992;33(8):1444–50.PubMed Dae MW, De Marco T, Botvinick EH, O’Connell JW, Hattner RS, Huberty JP, et al. Scintigraphic assessment of MIBG uptake in globally denervated human and canine hearts--implications for clinical studies. J Nucl Med 1992;33(8):1444–50.PubMed
18.
go back to reference Arbab AS, Koizumi K, Takano H, Uchiyama G, Arai T, Mera K. Parameters of dynamic and static iodine-123-MIBG cardiac imaging. J Nucl Med 1995;36(6):962–8.PubMed Arbab AS, Koizumi K, Takano H, Uchiyama G, Arai T, Mera K. Parameters of dynamic and static iodine-123-MIBG cardiac imaging. J Nucl Med 1995;36(6):962–8.PubMed
19.
go back to reference Arimoto T, Takeishi Y, Fukui A, Tachibana H, Nozaki N, Hirono O, et al. Dynamic 123I-MIBG SPECT reflects sympathetic nervous integrity and predicts clinical outcome in patients with chronic heart failure. Ann Nucl Med 2004;18(2):145–50.PubMedCrossRef Arimoto T, Takeishi Y, Fukui A, Tachibana H, Nozaki N, Hirono O, et al. Dynamic 123I-MIBG SPECT reflects sympathetic nervous integrity and predicts clinical outcome in patients with chronic heart failure. Ann Nucl Med 2004;18(2):145–50.PubMedCrossRef
20.
go back to reference Henderson EB, Kahn JK, Corbett JR, Jansen DE, Pippin JJ, Kulkarni P, et al. Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. Circulation 1988;78(5 Pt 1):1192–9.PubMedCrossRef Henderson EB, Kahn JK, Corbett JR, Jansen DE, Pippin JJ, Kulkarni P, et al. Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. Circulation 1988;78(5 Pt 1):1192–9.PubMedCrossRef
21.
Metadata
Title
The impact of acquisition time of planar cardiac 123I-MIBG imaging on the late heart to mediastinum ratio
Authors
Aukelien C. Dimitriu-Leen
Alessia Gimelli
Imad al Younis
Caroline E. Veltman
Hein J. Verberne
Ron Wolterbeek
Silvia Zandbergen-Harlaar
Jeroen J. Bax
Arthur J. H. A. Scholte
Publication date
01-02-2016
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 2/2016
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-015-3220-5

Other articles of this Issue 2/2016

European Journal of Nuclear Medicine and Molecular Imaging 2/2016 Go to the issue